BioCryst Pharmaceuticals (BCRX) Set to Release Quarterly Earnings on Wednesday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is anticipated to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.0919 per share and revenue of $165.67 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to analyst estimates of $183.28 million. During the same period in the previous year, the company earned $0.15 EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 33.6% on a year-over-year basis. On average, analysts expect BioCryst Pharmaceuticals to post ($2.28) EPS for the current fiscal year and $0.72 EPS for the next fiscal year.

BioCryst Pharmaceuticals Stock Up 2.8%

Shares of BCRX opened at $8.10 on Wednesday. BioCryst Pharmaceuticals has a 12-month low of $6.23 and a 12-month high of $11.22. The business has a 50-day simple moving average of $8.71 and a two-hundred day simple moving average of $8.71.

Wall Street Analyst Weigh In

BCRX has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Wedbush lowered their price objective on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their price objective on BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Wednesday, September 30th. Cantor Fitzgerald raised their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $16.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $19.44.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.